These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31127909)

  • 1. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.
    Mohammed AA; Rashed HE; Abdelrahman AE; Obaya AA; Toam M; Abdel Nour HM; Abdelhamid MI; Elsayed FM
    Asian Pac J Cancer Prev; 2019 May; 20(5):1463-1470. PubMed ID: 31127909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 5. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
    J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
    Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
    J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
    Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
    Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma.
    Kawamoto K; Miyoshi H; Yoshida N; Nakamura N; Ohshima K; Sone H; Takizawa J
    Cancer Sci; 2016 Jun; 107(6):853-61. PubMed ID: 27027803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
    Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
    Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.